Back to Resources
Market Highlights
-
AstraZeneca and Daiichi Sankyo announced that Enhertu was granted Priority Review status.
-
Materials touted the drug’s availability in Japan for HER2-positive metastatic gastric cancer.
-
Readers were informed about the brand’s approval in Japan for HER2-positive solid tumors.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com